Effect of PD-1 Inhibitor Combined with X-Ray Irradiation on the Inflammatory Microenvironment and Lung Tissue Injury in Mice

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Doi T, Piha-Paul SA, Jalal SI, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal cCarcinoma. J Clin Oncol. 2018;36(1):61–67. doi:10.1200/JCO.2017.74.9846
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50. J Clin Oncol. 2021;39(21):2339–2349. doi:10.1200/JCO.21.00174
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi:10.1126/science.aar4060
   PubMed Web of Science ®Google Scholar
• Demaria S, Coleman CN, Formenti SC. Radiotherapy: changing the game in immunotherapy. Trends Cancer. 2016;2(6):286–294. doi:10.1016/j.trecan.2016.05.002
   PubMed Web of Science ®Google Scholar
• Wirsdorfer F, Cappuccini F, Niazman M, et al. Thorax irradiation triggers a local and systemic accumulation of immunosuppressive CD4+ FoxP3+ regulatory T cells. Radiat Oncol. 2014;9(1):98. doi:10.1186/1748-717X-9-98
   PubMed Web of Science ®Google Scholar
• Ying HJ, Fang M, Chen M. Progress in the mechanism of radiation-induced lung injury. Chin Med J. 2020;134(2):161–163. doi:10.1097/CM9.0000000000001032
   PubMed Web of Science ®Google Scholar
• Suresh K, Naidoo J, Lin CT, Danoff S. Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities. Chest. 2018;154(6):1416–1423. doi:10.1016/j.chest.2018.08.1048
   PubMed Web of Science ®Google Scholar
• Suresh K, Voong KR, Shankar B, et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J Thorac Oncol. 2018;13(12):1930–1939. doi:10.1016/j.jtho.2018.08.2035
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al.; PACIFIC Investigators. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–2350. doi:10.1056/NEJMoa1809697
   PubMed Web of Science ®Google Scholar
• Durm GA, Jabbour SK, Althouse SK, et al. A Phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. Cancer. 2020;126(19):4353–4361. doi:10.1002/cncr.33083
   PubMed Web of Science ®Google Scholar
• Peters S, Felip E, Dafni U, et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. Lung Cancer. 2019;133:83–87. doi:10.1016/j.lungcan.2019.05.001
   PubMed Web of Science ®Google Scholar
• Voong KR, Hazell SZ, Fu W, et al. Relationship between prior radiotherapy and checkpoint-inhibitor pneumonitis in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2019;20(4):e470–e479. doi:10.1016/j.cllc.2019.02.018
   PubMed Web of Science ®Google Scholar
• Nichols D, Boyle TA, Noyes D, et al. Evaluation of combined anti-PD-1 immunotherapy and radiation therapy in a preclinical mouse model of pneumonitis and fibrosis. J Thorac Dis. 2018;10(11):6254–6260. doi:10.21037/jtd.2018.10.01
   PubMed Web of Science ®Google Scholar
• Wang F, Luo Y, Tian X, et al. Impact of radiotherapy concurrent with anti-PD-1 therapy on the lung tissue of tumor-bearing mice. Radiat Res. 2019;191(3):271–277. doi:10.1667/RR15182.1
   PubMed Web of Science ®Google Scholar
• Jackson IL, Xu PT, Nguyen G, et al. Characterization of the dose response relationship for lung injury following acute radiation exposure in three well-established murine strains: developing an interspecies bridge to link animal models with human lung. Health Phys. 2014;106(1):48–55. doi:10.1097/HP.0b013e3182a32ccf
   PubMed Web of Science ®Google Scholar
• Matej R, Housa D, Pouckova P, Zadinova M, Olejar T. Radiation-induced production of PAR-1 and TGF-beta 1 mRNA in lung of C57Bl6 and C3H murine strains and influence of pharmacoprophylaxis by ACE inhibitors. Pathol Res Pract. 2007;203(2):107–114. doi:10.1016/j.prp.2006.10.006
   PubMed Web of Science ®Google Scholar
• Downing L, Sawarynski KE, Li J, McGonagle M, Sims MD, Marples B. A simple quantitative method for assessing pulmonary damage after x irradiation. Radiat Res. 2010;173(4):536–544. doi:10.1667/RR1712.1
   PubMed Web of Science ®Google Scholar
• Hanania AN, Mainwaring W, Ghebre YT, Hanania NA, Ludwig M. Radiation-induced lung injury: assessment and management. Chest. 2019;156(1):150–162. doi:10.1016/j.chest.2019.03.033
   PubMed Web of Science ®Google Scholar
• Mrass P, Oruganti SR, Fricke GM, et al. ROCK regulates the intermittent mode of interstitial T cell migration in inflamed lungs. Nat Commun. 2017;8(1):1010. doi:10.1038/s41467-017-01032-2
   PubMed Web of Science ®Google Scholar
• Du S, Zhou L, Alexander GS, et al. PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes. J Thorac Oncol. 2018;13(4):510–520. doi:10.1016/j.jtho.2017.12.002
   PubMed Web of Science ®Google Scholar
• Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589–595. doi:10.1182/blood-2009-02-206870
   PubMed Web of Science ®Google Scholar
• Lai JZ, Zhu YY, Ruan M, Chen L, Zhang QY. Local irradiation sensitized tumors to adoptive T cell therapy via enhancing the cross-priming, homing, and cytotoxicity of antigen-specific CD8 T cells. Front Immunol. 2019;10:2857. doi:10.3389/fimmu.2019.02857
   PubMed Web of Science ®Google Scholar
• Chen Y, Hyrien O, Williams J, Okunieff P, Smudzin T, Rubin P. Interleukin (IL)-1A and IL-6: applications to the predictive diagnostic testing of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2005;62(1):260–266. doi:10.1016/j.ijrobp.2005.01.041
   PubMed Web of Science ®Google Scholar
• Tabata C, Kubo H, Tabata R, et al. All-trans retinoic acid modulates radiation-induced proliferation of lung fibroblasts via IL-6/IL-6R system. Am J Physiol Lung Cell Mol Physiol. 2006;290(3):L597–L606. doi:10.1152/ajplung.00282.2005
   PubMed Web of Science ®Google Scholar
• Fishman JA, Hogan JI, Maus MV. Inflammatory and infectious syndromes associated with cancer immunotherapies. Clin Infect Dis. 2019;69(6):909–920. doi:10.1093/cid/ciy1025
   PubMed Web of Science ®Google Scholar
• Saito A, Horie M, Nagase T. TGF-β signaling in lung health and disease. Int J Mol Sci. 2018;19(8):2460. doi:10.3390/ijms19082460
   PubMed Web of Science ®Google Scholar
• Wang S, Campbell J, Stenmark MH, et al. Plasma levels of IL-8 and TGF-β1 predict radiation-induced lung toxicity in non-small cell lung cancer: a validation study. Int J Radiat Oncol Biol Phys. 2017;98(3):615–621. doi:10.1016/j.ijrobp.2017.03.011
   PubMed Web of Science ®Google Scholar
• Alam A, Mukhopadhyay ND, Ning Y, et al. A preliminary study on racial differences in HMOX1, NFE2L2, and TGFβ1 gene polymorphisms and radiation-induced late normal tissue toxicity. Int J Radiat Oncol Biol Phys. 2015;93(2):436–443. doi:10.1016/j.ijrobp.2015.05.049
   PubMed Web of Science ®Google Scholar
• Stenmark MH, Cai XW, Shedden K, et al. Combining physical and biologic parameters to predict radiation-induced lung toxicity in patients with non-small-cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys. 2012;84(2):e217–e222. doi:10.1016/j.ijrobp.2012.03.067
   PubMed Web of Science ®Google Scholar
• Barcellos-Hoff MH, Dix TA. Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol. 1996;10(9):1077–1083. doi:10.1210/mend.10.9.8885242
   PubMedGoogle Scholar
• Judge JL, Owens KM, Pollock SJ, et al. Ionizing radiation induces myofibroblast differentiation via lactate dehydrogenase. Am J Physiol Lung Cell Mol Physiol. 2015;309(8):L879–L887. doi:10.1152/ajplung.00153.2015
   PubMed Web of Science ®Google Scholar
• Rube CE, Uthe D, Schmid KW, et al. Dose-dependent induction of transforming growth factor beta (TGF-beta) in the lung tissue of fibrosis-prone mice after thoracic irradiation. Int J Radiat Oncol Biol Phys. 2000;47(4):1033–1042. doi:10.1016/S0360-3016(00)00482-X
   PubMed Web of Science ®Google Scholar
• Yang X, Ni J, Li Y, et al. LncRNA-RP11 modulates TGF-β1-activated radiation-induced lung injury through downregulating microRNA-29a. Dose Response. 2020;18(4):1559325820949071. doi:10.1177/1559325820949071
   Web of Science ®Google Scholar
• Heukels P, Moor CC, von der Thusen JH, Wijsenbeek MS, Kool M. Inflammation and immunity in IPF pathogenesis and treatment. Respir Med. 2019;147:79–91. doi:10.1016/j.rmed.2018.12.015
   PubMed Web of Science ®Google Scholar
• Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2014;58:13–19. doi:10.1016/j.ejps.2014.02.014
   PubMed Web of Science ®Google Scholar
• Ying H, Fang M, Hang QQ, Chen Y, Qian X, Chen M. Pirfenidone modulates macrophage polarization and ameliorates radiation-induced lung fibrosis by inhibiting the TGF-β1/Smad3 pathway. J Cell Mol Med. 2021;25(18):8662–8675. doi:10.1111/jcmm.16821
   PubMed Web of Science ®Google Scholar
• Flechsig P, Dadrich M, Bickelhaupt S, et al. LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-β and BMP-associated proinflammatory and proangiogenic signals. Clin Cancer Res. 2012;18(13):3616–3627. doi:10.1158/1078-0432.CCR-11-2855
   PubMed Web of Science ®Google Scholar
• Vanpouille-Box C, Diamond JM, Pilones KA, et al. TGFβ is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res. 2015;75(11):2232–2242. doi:10.1158/0008-5472.CAN-14-3511
   PubMed Web of Science ®Google Scholar
• Derynck R, Turley SJ, Akhurst RJ. TGFβ biology in cancer progression and immunotherapy. Nat Rev Clin Oncol. 2021;18(1):9–34. doi:10.1038/s41571-020-0403-1
   PubMed Web of Science ®Google Scholar